Literature DB >> 4703226

Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

A D Schreiber, A P Kaplan, K F Austen.   

Abstract

Highly purified inhibitor of the first component of complement (CāINH) was shown to inhibit the capacity of active Hageman factor fragments to initiate kinin generation, fibrinolysis, and coagulation. The inhibition of prealbumin Hageman factor fragments observed was dependent upon the time of interaction of the fragments with CāINH and not to an effect upon kallikrein or plasmin generated. The inhibition of the coagulant activity of the intermediate sized Hageman factor fragment by CāINH was not due to an effect on PTA or other clotting factors. The inhibition by CāINH of both the prealbumin and intermediate sized Hageman factor fragments occurred in a dose response fashion. The CāINH did not appear to be consumed when the activity of the Hageman factor fragments was blocked, although the fragments themselves could no longer be recovered functionally or as a protein on alkaline disc gel electrophoretic analysis. These results suggest that the CāINH may have an enzymatic effect on the fragments or that an additional site on CāINH is involved in Cā inactivation.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4703226      PMCID: PMC302404          DOI: 10.1172/JCI107313

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors.

Authors:  D Ogston; C M Ogston; O D Ratnoff; C D Forbes
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

4.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

6.  Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.

Authors:  C D Forbes; J Pensky; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1970-11

7.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema.

Authors:  F S Rosen; C A Alper; J Pensky; M R Klemperer; V H Donaldson
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

9.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  39 in total

1.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

2.  Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

Authors:  M van Geffen; M Cugno; P Lap; A Loof; M Cicardi; W van Heerde
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 3.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 4.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

5.  The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.

Authors:  S D Revak; C G Cochrane
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

6.  [Relations between complement and blood coagulation (author's transl)].

Authors:  G Müller-Berghaus
Journal:  Klin Wochenschr       Date:  1977-07-15

Review 7.  Hereditary angioedema in childhood: an approach to management.

Authors:  Didier G Ebo; Marjoke M Verweij; Kathleen J De Knop; Margo M Hagendorens; Chris H Bridts; Luc S De Clerck; Wim J Stevens
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

8.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

9.  C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.

Authors:  G Doekes; L A van Es; M R Daha
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

10.  The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator.

Authors:  A P Kaplan; E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.